Opportunity Information: Apply for PA 16 074
Apply for PA 16 074
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Behavioral and Integrative Treatment Development Program (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279,.
- This funding opportunity was created on Jan 08, 2016 and posted on Jan 08, 2016.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Behavioral and Integrative Treatment Development Program (R03) (Funding Opportunity Number PA-16-074) is a National Institutes of Health (NIH) discretionary grant opportunity (HHS-NIH11) designed to support small, focused research projects that can be finished within a two-year period. It uses the NIH R03 mechanism, which is typically meant for discrete, well-defined studies rather than large, multi-site trials or long programmatic lines of work. The overall goal is to move promising behavioral and integrated treatment ideas forward through early-stage development work, especially in areas where substance use, HIV risk, treatment adherence, and chronic pain intersect.
This opportunity is centered on developing and refining behavioral interventions and integrated interventions, meaning approaches that may combine behavioral strategies with pharmacological treatment components. NIH is looking for projects that directly target one or more of the following areas: substance abuse; prevention of HIV acquisition or transmission among individuals who are in drug abuse treatment; improving adherence to drug abuse treatment and to medications used for HIV and addiction; and chronic pain. In practical terms, the program is meant to help researchers build, test, and sharpen interventions that can later be evaluated in larger and more definitive trials, while also paying attention to how and why the intervention works.
A key emphasis of the FOA is Stage I treatment development research. Examples of responsive projects include Stage I intervention generation, where investigators design or assemble new intervention content, protocols, and delivery strategies grounded in theory, clinical insight, or prior evidence. It also includes Stage I pilot or feasibility studies that check whether an intervention is acceptable to participants, practical to deliver, and promising enough to justify more expensive next-step research. In both intervention generation and pilot/feasibility work, NIH highlights the importance of identifying and developing putative moderators, mediators, and mechanisms of change. That means applicants are encouraged to think beyond whether an intervention is feasible and begin specifying who it works best for (moderators), what intermediate processes it changes (mediators), and the underlying pathways responsible for improvement (change mechanisms). This focus is intended to strengthen the science early, so later trials can be more targeted, interpretable, and efficient.
The announcement also points to Stage I studies aimed at generating or refining drug abuse treatment approaches or adherence interventions, which can include improving engagement, retention, medication-taking behavior, and follow-through with treatment plans. Another highlighted direction is Stage I research that tries to boost intervention effects and increase implementability, including creative use of technology or other methods that make an intervention easier to deliver in real-world settings. Technology could include digital tools for skills practice, adherence supports, remote coaching, mobile assessments, telehealth delivery, or other scalable components, as long as the work remains aligned with early-stage development and testing.
From an eligibility standpoint, the FOA is broad and open to many organization types. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses, along with other applicants as allowed in the FOA’s additional eligibility language. The program is categorized under Education and Health and is associated with CFDA numbers 93.273 and 93.279.
In terms of timing and funding parameters provided in the source data, the FOA was posted on January 8, 2016, and lists a closing date of January 7, 2019 (both original and current closing dates match in the provided record). The listed award ceiling is $50,000, reflecting the small-grant nature of the R03 mechanism and reinforcing that NIH is looking for tightly scoped studies with clear aims that can be completed quickly. While the record includes an "ExpectedAwards" field, the number is not specified in the provided data, so applicants would typically look to NIH guidance or the full announcement for any additional context on anticipated volume.
Overall, this opportunity is best viewed as support for the early steps of intervention science in substance use, HIV-related risk and treatment contexts, adherence, and chronic pain. Strong applications will usually propose a compact, realistic set of aims, show a clear line from the intervention concept to measurable targets, and include an explicit plan for examining early signals of efficacy alongside feasibility and acceptability, while also laying groundwork for understanding mechanisms and tailoring future versions of the intervention.
Frequently Asked Questions (FAQs)
What is the Behavioral and Integrative Treatment Development Program (R03) (PA-16-074)?
PA-16-074 is a National Institutes of Health (NIH) discretionary funding opportunity that uses the NIH R03 small grant mechanism. It is designed to support small, focused research projects that can be completed within a two-year period, with an emphasis on early-stage development and refinement of behavioral and integrated treatment approaches.
What is the main goal of this funding opportunity?
The goal is to move promising behavioral and integrated treatment ideas forward through early-stage treatment development research, especially where substance use, HIV risk, treatment adherence, and chronic pain intersect. The program is intended to help investigators develop, test, and sharpen interventions so they are ready for later evaluation in larger, more definitive trials.
What does NIH mean by "behavioral" and "integrated" interventions in this FOA?
Behavioral interventions refer to approaches that use behavioral strategies to change outcomes (for example, engagement, adherence, risk behaviors, or coping). Integrated interventions, as described here, may combine behavioral strategies with pharmacological treatment components. The FOA emphasizes development and refinement work for both types of approaches.
What topic areas does this R03 opportunity directly target?
Projects should directly target one or more of the following areas: substance abuse; prevention of HIV acquisition or transmission among individuals in drug abuse treatment; improving adherence to drug abuse treatment and to medications used for HIV and addiction; and chronic pain.
What kinds of studies are a good fit for the NIH R03 mechanism?
The R03 mechanism is typically meant for discrete, well-defined studies rather than large, multi-site trials or long programmatic lines of work. For this FOA, that generally means compact projects with clear, realistic aims that can be completed within two years.
How long can an R03 project last under this program?
This opportunity is designed for projects that can be finished within a two-year period.
What is the maximum award amount listed for this opportunity?
The listed award ceiling is $50,000, reflecting the small-grant nature of the R03 mechanism and reinforcing the expectation of a tightly scoped study.
What stage of research does this FOA emphasize?
A key emphasis is Stage I treatment development research. This includes early work to generate, refine, and preliminarily test interventions before moving to larger and more definitive trials.
What is "Stage I intervention generation" in the context of this FOA?
Stage I intervention generation refers to designing or assembling new intervention content, protocols, and delivery strategies. The FOA notes that this work should be grounded in theory, clinical insight, or prior evidence.
What is meant by Stage I pilot or feasibility studies here?
Stage I pilot or feasibility studies are early tests that examine whether an intervention is acceptable to participants, practical to deliver, and promising enough to justify more expensive next-step research.
Does NIH expect projects to look at more than just feasibility and acceptability?
Yes. NIH highlights the importance of identifying and developing putative moderators, mediators, and mechanisms of change. Applicants are encouraged to start specifying who the intervention works best for (moderators), what intermediate processes it changes (mediators), and the pathways responsible for improvement (mechanisms of change).
What are moderators, mediators, and mechanisms of change (as described in the FOA summary)?
Moderators refer to factors that help indicate who an intervention works best for. Mediators are intermediate processes the intervention changes on the way to improving outcomes. Mechanisms of change are the underlying pathways responsible for improvement. The FOA encourages applicants to develop these elements early to strengthen later trials.
Does this FOA support research focused on drug abuse treatment and adherence interventions?
Yes. The FOA points to Stage I studies aimed at generating or refining drug abuse treatment approaches or adherence interventions, including work to improve engagement, retention, medication-taking behavior, and follow-through with treatment plans.
Is technology allowed or encouraged in proposed interventions?
Yes. The FOA highlights Stage I research that aims to boost intervention effects and increase implementability, including creative use of technology or other methods that make an intervention easier to deliver in real-world settings.
What are examples of technology components that could fit within this FOA?
The FOA summary describes possible technology uses such as digital tools for skills practice, adherence supports, remote coaching, mobile assessments, telehealth delivery, or other scalable components, as long as the work stays aligned with early-stage development and testing.
What does the FOA mean by improving "implementability"?
In this context, implementability refers to making an intervention easier to deliver in real-world settings. The FOA highlights approaches (including technology) that can improve how practical and scalable an intervention is while it is being developed and refined in Stage I research.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses, along with other applicants as allowed in the FOA's additional eligibility language.
Is this opportunity limited to universities and academic medical centers?
No. The eligibility language provided is broad and includes many organization types beyond higher education institutions, including governments, tribal entities, nonprofits, for-profits (other than small businesses), and small businesses.
Is this grant categorized under a specific area?
Yes. The program is categorized under Education and Health in the provided information.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.273 and 93.279.
When was this funding opportunity posted?
The FOA was posted on January 8, 2016.
What is the closing date listed for this FOA in the provided record?
The provided record lists a closing date of January 7, 2019 (and indicates the original and current closing dates match in that record).
How many awards does NIH expect to make under this opportunity?
The provided source data includes an "ExpectedAwards" field, but the number is not specified in the information provided. Applicants would typically consult NIH guidance or the full announcement for additional context on anticipated award volume.
What makes an application competitive based on the provided description?
Based on the description provided, strong applications will usually propose a compact and realistic set of aims; show a clear line from the intervention concept to measurable targets; include a plan for examining early signals of efficacy alongside feasibility and acceptability; and lay groundwork for understanding mechanisms and for tailoring future versions of the intervention.
Is this opportunity intended to support large multi-site trials?
No. The NIH R03 mechanism is described as typically meant for discrete, well-defined studies rather than large, multi-site trials or long programmatic lines of work.
What is the larger research path NIH seems to be encouraging with this FOA?
The FOA supports early intervention science steps: generating and refining interventions, testing feasibility and acceptability, and identifying mediators/moderators/mechanisms so that later studies can be more targeted, interpretable, and efficient in larger and more definitive trials.
Browse more opportunities from the same category: Education, Health
Next opportunity: Mozambique: Supporting Indigenous Organizations to implement and Expand Comprehensive HIV/AIDS Prevention, Care and Treatment in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR)
Previous opportunity: Hispanic-Serving Institutions (HSI) Education Grants Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 074
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 074) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Emerging Questions in Cancer Systems Biology (U01) Apply for PAR 16 131 Funding Number: PAR 16 131 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25) Apply for PAR 16 138 Funding Number: PAR 16 138 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| The Early Detection Research Network: Biomarker Developmental Laboratories (U01) Apply for RFA CA 16 009 Funding Number: RFA CA 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 074", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.